Results
Of 62 patients included in the trial, 31 received panitumumab plus trifluridine-tipiracil (19 [61.3%] male; median age, 65 years [range, 39-81 years]) (arm B) and 31 received trifluridine-tipiracil only (17 [54.8%] male; median age, 66 years [range, 32-82 years]) (arm A) (